Incyte Corporation

Denovo Biopharma LLC

Denovo Biopharma (hangzhou) Ltd. Co.

Denovo Biomarkers Inc.

Wen Luo

Henry Yue

Mariah R Baughn

Ernestine A Lee

April J A Hafalia

Ameena R Gandhi

Monique G Yao

Yan Lu

Anita Swarnakar

Craig H Ison

Danniel B Nguyen

Vicki S Elliott

Rajagopal Gururajan

Michael B Thornton

Thomas W Richardson

Joseph P Marquis

Ian J Forsythe

Shanya D Becha

Pei Jin

Soo Yeun Lee

Reena Khare

Uyen K Tran

Joana X Li

Amy D Wilson

Narinder K Chawla-Walia

Hong Sun

The present invention describes biomarkers that have been discovered to correlate with varied individual responses (e.g., efficacy, adverse effect, and other end points) to enzastaurin, in treating diseases such as, DLBCL, GBM, and other cancer types. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might not be beneficial, by the treatment.

Methods and composition for the prediction of the activity of enzastaurin

The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.

Methods and compositions of predicting activity of retinoid X receptor modulator

Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Antibodies to human &#x3b2;-adrenergic receptor kinase

Human &#x3b2;-adrenergic receptor kinase polypeptide and methods

Various embodiments of the invention provide human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

Human &#x3b2;-adrenergic receptor kinase nucleic acid molecule

Growing community of inventors

San Diego, CA, United States of America

Wen Luo